心臟衰竭係因心臟充填或輸出血液的功能受損，藥物治療主要目的在於減少心臟負擔，新的機轉的藥品血管張力素受體-腦啡肽酶抑制劑，目前僅有Entresto(sacubitril/valsartan)一種藥品。本研究結果顯示患有心臟衰竭的病人，在服用sacubitril/valsartan前若已有偏低的左心室射出分率，預期將較有機會在服用後得到更好的射出分率提高效果，且此種效果在720日的時間跨度內，繼續服用仍能保持有效。本研究病人之心臟衰竭累積首次住院率雖較該藥PARADIGM-HF樞紐試驗結果略低，但並無足夠統計差異，研究結果也未顯示前測是否屬於低射出分率會影響到心臟衰竭首次入院比率。

Heart failure is caused by insufficient heart filling or output. Therapeutic drugs for heart failure treatment focus to lower the burden on the heart. A newcomer Entresto (Sacubitril/Valsartan) which is the first in class of angiotensin receptor-neprilysin inhibitor (ARNI) is the only one available in market currently. The results of this study show that heart failure patients with lower left ventricular ejection fraction (LVEF) before taking sacubitril/valsartan have a better chance of getting a higher LVEF improvement after taking the medicine. The LVEF increase remains effective until 720 days from the drug initialized if patients keep taking the medicine. The cumulative probability of first hospitalization for heart failure in this study is slightly lower than the results of the PARADIGM-HF pivotal trial without statistical significance. This study does not show whether the patients’ baseline LVEF greater than 35% relates to cumulative probability of first hospitalization for heart failure with statistical significance.